UPDATE: MLV & Co Reiterates Buy Rating, Raises PT on TG Therapeutics on Multiple Positive Factors

In a report published Wednesday, MLV & Co analyst Graig C. Suvannavejh reiterated a Buy rating on

, and raised the price target from $10.00 to $16.00. In the report, MLV & Co noted, “We now raise our PT on TGTX to $16 (vs. our prior $10) on: 1) flawless execution with lead assets TG-1101 and TGR-1202; 2) a favorable view of TGTX's in-licensing of a novel IRAK4 inhibitor program; and 3) a strong belief that data for TGTX's proprietary '1101 + '1202 combination at next month's Pan Pacific Lymphoma Conference will be positive. Thus, ahead of a significant upcoming catalyst, and a view that TGTX will ultimately present as a very attractive takeout candidate, we maintain our Buy rating and reiterate TGTX as one of our top ideas.” TG Therapeutics closed on Tuesday at $9.99.